Russell Investments Group
ORMP icon

Russell Investments Group’s Oramed Pharmaceuticals ORMP Stock Holding History

Russell Investments Group’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-250
Closed -$643 – 3766
2024
Q2 		$643 Buy
+250
New +$594 ﹤0.01% 3479
2023
Q1 		– Sell
-56,516
Closed -$680K – 3356
2022
Q4 		$680K Buy
+56,516
New +$439K ﹤0.01% 2159
2022
Q2 		– Sell
-43,013
Closed -$371K – 2948
2022
Q1 		$371K Sell
43,013
-54,097
-56% -$554K ﹤0.01% 2314
2021
Q4 		$1.39M Sell
97,110
-5,763
-6% -$120K ﹤0.01% 1996
2021
Q3 		$2.26M Buy
+102,873
New +$1.75M ﹤0.01% 1764

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Russell Investments Group's ORMP Position: Q3 2024 in Review

Russell Investments Group sold out of Oramed Pharmaceuticals (ORMP) in Q3 2024, closing a stake of 250 shares — an estimated $643 sold.

Russell Investments Group first reported a position in ORMP in Q3 2021 and held it in 5 quarters. The position peaked at $2.26M in Q3 2021. 55 funds tracked by Wall St. Rank hold ORMP as of Q3 2024.

  • Russell Investments Group reported no remaining Oramed Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Russell Investments Group sold 250 Oramed Pharmaceuticals shares in Q3 2024, an estimated $643.
  • Russell Investments Group first reported a position in Oramed Pharmaceuticals in Q3 2021 and held it in 5 quarters.
  • Russell Investments Group's Oramed Pharmaceuticals position peaked at $2.26M in Q3 2021.
  • 55 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2024.

Based on Russell Investments Group's 13F filing for Q3 2024, filed 13 Nov 2024.